Back to discover
Drug

Satraplatin

In clinical development
Emerging researchLate-stage development
RxNorm1733681ChEMBLCHEMBL3833367ATCL01XA04UNII8D7B37T28G
1
Research papers
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

A Phase II Study of Satraplatin and Prednisone in Metastatic Androgen Independent Prostate Cancer (AIPC)

Clinical trial2018-10-02Results posted · ClinicalTrials.gov

Phase II Trial of Bevacizumab and Satraplatin in Docetaxel Treated Metastatic Androgen Independent Prostate Cancer

Clinical trial2018-06-12Results posted · ClinicalTrials.gov

Predicting Response to Platinum Chemotherapy in Metastatic Castration Resistant Prostate Ca(mCRPC)Using a Genomic Signature for "BRCAness": A Phase II Prospective Open Label Clinical Trial of Satraplatin in Men With mCRPC Who Have Progressed on Docetaxel

Clinical trial2018-02-13Results posted · ClinicalTrials.gov

The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs.

Research2016-02-11Chemical reviews

A Phase I Trial and Pharmacokinetic Study of the Oral Platinum Analog Satraplatin in Children and Young Adults With Refractory Solid Tumors Including Brain Tumors

Clinical trial2015-05-29Completed · ClinicalTrials.gov

Phase I Dose Finding Study of the Orally Bioavailable Platinum Analog Satraplatin in Combination With Abraxane (Paclitaxel Protein-bound Particles) in Advanced Cancers

Clinical trial2010-06-01Completed · ClinicalTrials.gov

Expanded Access Study of Satraplatin Plus Prednisone in Patients With Hormone Refractory Prostate Cancer (HRPC) Previously Treated With Unlimited Cytotoxic Chemotherapy Regimen (SPERA)

Clinical trial2009-12-01Terminated · ClinicalTrials.gov

A Phase 2 Study Comparing Sequential Satraplatin and Erlotinib to Single-Agent Erlotinib in Patients ≥ 70 Years of Age With Unresectable Stage 3 OR 4 Non-Small Cell Lung Cancer as 1st-Line Therapy

Clinical trial2009-03-01Completed · ClinicalTrials.gov

A Phase I Study of the Oral Platinum Agent Satraplatin in Combination With Weekly Docetaxel

Clinical trial2009-03-01Terminated · ClinicalTrials.gov

A Phase 1/2 Study With Satraplatin and Simultaneous Radiation in Locally Advanced Non-Small Cell Lung Cancer

Clinical trial2009-02-01Terminated · ClinicalTrials.gov

Phase II of Oral Satraplatin in Patients With Metastatic Breast Cancer (MBC)

Clinical trial2008-02-01Completed · ClinicalTrials.gov

A Multi-National Phase III Study of Satraplatin Plus Prednisone or Placebo Plus Prednisone in Patients With Hormone Refractory Prostate Cancer Previously Treated With One Cytotoxic Chemotherapy Regimen

Clinical trial2007-03-01Completed · ClinicalTrials.gov

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Satraplatin
RxNorm CUI
1733681
ChEMBL ID
CHEMBL3833367
ATC codes
L01XA04
UNII
8D7B37T28G

Clinical trials

11 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
11
registered trials across all phases
LATEST COMPLETION 2015
3
Late-stage (III+)
8
Completed
3
Discontinued
PHASE DISTRIBUTIONn = 11
Phase 13Phase 1 / 21Phase 24Phase 32Phase N / A1

Recent completions

Trials that read out recently, adding to the completed evidence base.

A Phase I Trial and Pharmacokinetic Study of the Oral Platinum Analog Satraplatin in Children and Young Adults With Refractory Solid Tumors Including Brain Tumors

CompletedPH INational Cancer Institute (NCI)n=92015

Predicting Response to Platinum Chemotherapy in Metastatic Castration Resistant Prostate Ca(mCRPC)Using a Genomic Signature for "BRCAness": A Phase II Prospective Open Label Clinical Trial of Satraplatin in Men With mCRPC Who Have Progressed on Docetaxel

CompletedPH IIWilliam K. Ohn=132013

Phase II Trial of Bevacizumab and Satraplatin in Docetaxel Treated Metastatic Androgen Independent Prostate Cancer

CompletedN/ABarbara Ann Karmanos Cancer Instituten=312012

A Phase II Study of Satraplatin and Prednisone in Metastatic Androgen Independent Prostate Cancer (AIPC)

CompletedPH IINational Cancer Institute (NCI)n=242012

Phase I Dose Finding Study of the Orally Bioavailable Platinum Analog Satraplatin in Combination With Abraxane (Paclitaxel Protein-bound Particles) in Advanced Cancers

CompletedPH IYale Universityn=152010

A Phase 2 Study Comparing Sequential Satraplatin and Erlotinib to Single-Agent Erlotinib in Patients ≥ 70 Years of Age With Unresectable Stage 3 OR 4 Non-Small Cell Lung Cancer as 1st-Line Therapy

CompletedPH IIAgennixn=1002009

Research activity

1 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Journals, researchers & institutions
Top journals
  • Chemical reviews1
Leading researchers
  • Johnstone TC1
  • Lippard SJ1
  • Suntharalingam K1
Leading institutions
free-text, unnormalised
  • King's College London1
  • Massachusetts Institute of Technology1
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials